Add to a list

Inactive Instrument

Lumos Pharma, Inc. Stock

LUMO

US55028X1090

Biotechnology & Medical Research

Latest news: Lumos Pharma, Inc.

12/12/24	Lumos Pharma, Inc.(NasdaqGM:LUMO) dropped from NASDAQ Composite Index	CI
12/12/24	Double Point Ventures LLC completed the acquisition of Lumos Pharma, Inc.	CI
12/12/24	Lumos Pharma, Inc.(NasdaqGM:LUMO) dropped from S&P TMI Index	CI
21/11/24	Lumos Pharma, Inc. Announces Updated Phase 2 OraGrowtH Data Presented at ESPE 2024	CI
07/11/24	Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24/10/24	HC Wainwright Downgrades Lumos Pharma to Neutral From Buy, Adjusts Price Target to $4.25 From $28	MT
23/10/24	Lumos Pharma Says it has Agreed to be Acquired by a Double Point Ventures Unit and Taken Private	MT
23/10/24	Double Point to Buy Lumos Pharma for $38 Million as FDA OKs Lumos Drug Trial	DJ
23/10/24	Double Point Ventures LLC entered into a definitive merger agreement to acquire Lumos Pharma, Inc. for $36.9 million.	CI
02/08/24	Oppenheimer Adjusts Lumos Pharma Price Target to $13 From $16, Maintains Outperform Rating	MT
02/08/24	Lumos Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
01/08/24	Lumos Pharma, Inc., Q2 2024 Earnings Call, Aug 01, 2024
01/08/24	Earnings Flash (LUMO) LUMOS PHARMA Reports Q2 Revenue $488,000, vs. Street Est of $0.13M	MT

More news

Analysts' recommendations: Lumos Pharma, Inc.

24/10/24	HC Wainwright Downgrades Lumos Pharma to Neutral From Buy, Adjusts Price Target to $4.25 From $28	MT
02/08/24	Oppenheimer Adjusts Lumos Pharma Price Target to $13 From $16, Maintains Outperform Rating	MT
11/12/23	Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating	MT
15/08/23	Cantor Fitzgerald Adjusts Lumos Pharma's Price Target to $10 From $14, Keeps Overweight Rating	MT
10/08/23	Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating	MT

More recommendations

Press Releases: Lumos Pharma, Inc.

12/12/24	Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma	GL
25/11/24	Lumos Pharma : Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM 201 to 24 Months in PGHD and Correlation of Growth to LUM 201’s Unique Pulsatile Mechanism of Action Form 8 K	PU
21/11/24	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action	AQ
21/11/24	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action	GL
08/11/24	Lumos: Q3 Earnings Snapshot	AQ

More press releases

News in other languages: Lumos Pharma, Inc.

21/12/19	Aktien New York Schluss: Rekorde - 'Anleger jagen dem Markt hinterher'
20/12/19	Aktien New York: Immer neue Rekorde - Investoren setzen auf die USA
31/07/15	Merck : Un vaccin contre Ebola se révèle efficace à 100%
31/07/15	NewLink Genetics : Premiers résultats du vaccin anti-Ebola "prometteurs"-OMS
08/01/15	Ebola-Essais cliniques en janvier et février en Afrique - OMS

More news

Managers and Directors: Lumos Pharma, Inc.

Manager	Title	Age	Since
Lori Lawley DFI	Director of Finance/CFO	42	04/07/2021
John McKew PSD	President	61	01/08/2021
Aleksandra K. Bruchey COO	Chief Operating Officer	-	01/05/2022

Director	Title	Age	Since
Christopher Uzpen BRD	Director/Board Member	-	12/12/2024
Daniel Yadegar BRD	Director/Board Member	-	-
Campbell Murray BRD	Director/Board Member	50	-

More insiders

Lumos Pharma LLC, formerly known as, Lumos Pharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product candidate, LUM-201, is an orally administered growth hormone secretagogue intended for the treatment of Pediatric Growth Hormone Deficiency (PGHD). The Companyâ€™s pipeline includes programs targeting growth hormone-related disorders and is supported by data from multiple clinical trials. Lumos Pharma engaged in strategic partnerships to expand its portfolio and leverage scientific in endocrinology, neurology, and metabolic diseases to advance drug development.

Employees

Sector

Biotechnology & Medical Research

More about the company

3 years	1.37	4.58
5 years	1.37	10.58
10 years	1.37	36.72

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/12/24 A	John McKew	Issuer sale	Chairperson	255,142	2.9501%
12/12/24 A	SHVMS, LLC	Issuer sale	Company	730,446	8.4458%
12/12/24 A	Bradley Powers	Issuer sale	Compliance Officer	89,807	1.0384%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LUMOS PHARMA, INC.	-.--%	-.--%	-	-	37.54M
Average	-.--%
Weighted average by Cap.	-.--%

Lumos Pharma, Inc. Stock

Stocks

LUMO

US55028X1090

Biotechnology & Medical Research

Latest news: Lumos Pharma, Inc.

Analysts' recommendations: Lumos Pharma, Inc.

Press Releases: Lumos Pharma, Inc.

News in other languages: Lumos Pharma, Inc.

Price Extremes

Managers and Directors: Lumos Pharma, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile